Printer Friendly

IXSYS INC. GRANTED WORLDWIDE EXCLUSIVE LICENSE BY THE UNIVERSITY OF CALIFORNIA

 IXSYS INC. GRANTED WORLDWIDE EXCLUSIVE LICENSE
 BY THE UNIVERSITY OF CALIFORNIA
 SAN DIEGO, Aug. 24 /PRNewswire/ -- Ixsys Inc., a leader in the area of monoclonal antibody and peptide engineering, announced that it has been granted worldwide exclusive license by the University of California to technology for the production of antigen-specific human monoclonal antibodies. The technology, discovered by Drs. Paula Boerner and Ivor Royston, formerly of U.C. San Diego, is considered a major breakthrough in generating human monoclonal antibodies in the laboratory. Ixsys believes that this is the first system that has consistently been able to produce human monoclonal antibodies outside the human body which are targeted against specific disease-associated antigens.
 Monoclonal antibodies are believed to be effective in the diagnosis and treatment of a wide range of human diseases including cancers, infectious diseases, cardiovascular and others. Most companies pursuing the development of monoclonal antibodies have used antibodies of non-human origin. These antibodies exhibit many of the same properties of a human antibody, but they also create problems in that the human body recognizes this non-human antibody as a foreign substance invading the body. This stimulates the human immune system to become activated and launch an attack against this invader. The net effect can be the neutralization of the intended treatment. It is widely believed that antibodies of a human source will eliminate this phenomenon.
 The human spleen is considered to be a major site of the generation of an antibody response in the human body. The system that Ixsys is working with consists of making a mixture of human spleen cells and exposing these mixtures to a disease-causing antigen. In a matter of weeks Ixsys scientists have been able to generate human monocional antibodies for a number of disease targets.
 Ixsys is using this breakthrough technology in combination with its proprietary methods for producing and enhancing antibodies applicable to the treatment of a wide range of disease states. These methods, which include means of rapidly changing an antibodies' performance characteristics are currently being applied to its research efforts in cancer and infectious diseases. The company believes that its arsenal of protein engineering techniques places it in a leadership position in this field.
 Ixsys is the exclusive licensee of this technology and has retained the right to grant sublicenses. No other details of the agreement have been disclosed.
 For more information contact Michael Hanifin 619-455-2356. Ixsys is located at 3550 General Atomics Court, Suite L-103, San Diego, CA 92121.
 -0- 8/24/92
 /CONTACT: Michael Hanifin of Ixsys, 619-455-2356/ CO: Ixsys Inc.; University of California ST: California IN: MTC SU: CON


EH-AL -- SD003 -- 2617 08/24/92 13:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1992
Words:440
Previous Article:BARR AND FDA RESUME NEGOTIATIONS
Next Article:CELLULAR ONE HAS RESPONSE TEAM IN FLORIDA TO HELP CLEAN UP HURRICANE AFTERMATH
Topics:


Related Articles
ONCOR SIGNS EXCLUSIVE LICENSING AGREEMENT FOR COMMERCIALIZATION OF p58 GENE, POTENTIAL SUPPRESSOR OF MALIGNANT MELANOMA AND OTHER TUMORS
STRATAGENE AND IXSYS ANNOUNCE SETTLEMENT OF TECHNOLOGY LITIGATION
BIOSITE DIAGNOSTICS AND IXSYS INC. ANNOUNCE RESEARCH AND DEVELOPMENT AGREEMENT
IXSYS AND BRISTOL-MYERS SQUIBB ANNOUNCE RESEARCH AGREEMENT ON TUMOR-ASSOCIATED ANTIBODIES
IXSYS SCIENTISTS REPORT ABILITY TO ENHANCE THERAPEUTIC VALUE OF MONOCLONAL ANTIBODIES BEYOND THAT ACHIEVED BY THE HUMAN IMMUNE SYSTEM
CALGENE, PLANT GENETIC SYSTEMS EXECUTE BROAD CROSS LICENSE AGREEMENTS; CALGENE GRANTS PLANT ANTISENSE LICENSE AND RECEIVES BT PATENT RIGHTS
Abgenix and Japan Tobacco Cross License Human Monoclonal Antibody Technology With GenPharm

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters